13:11:23 EDT Fri 07 May 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

News for U:ASLN from 2020-05-08 to 2021-05-07 - 22 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2021-05-05 05:23U:ASLNNews ReleaseASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology
2021-04-22 07:51U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
2021-03-18 07:27U:ASLNNews ReleaseASLAN Pharmaceuticals Appoints Dr Kathleen Metters as Independent Director
2021-03-03 00:43U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
2021-03-01 16:01U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
2021-03-01 06:00U:ASLNNews ReleaseASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
2021-02-25 06:30U:ASLNNews ReleaseASLAN Pharmaceuticals Announces $18 Million Private Placement
2021-02-18 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
2021-01-26 07:30U:ASLNNews ReleaseNew Research Published in Toxicology in Vitro Provides Insight Into the Hepatotoxicity of DHODH Inhibitors Suggesting ASLAN003 Has the Potential to Be Best-In-Class
2021-01-11 05:34U:ASLNNews ReleaseASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
2020-11-19 07:22U:ASLNNews ReleaseASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference
2020-11-09 07:00U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2020-10-22 07:30U:ASLNNews ReleaseASLAN Pharmaceuticals Initiates Third Dose Cohort of ASLAN004 in Atopic Dermatitis Clinical Trial
2020-10-16 05:25U:ASLNNews ReleaseASLAN Pharmaceuticals to Develop ASLAN003 as Next Generation DHODH Inhibitor in Autoimmune Conditions
2020-09-21 06:00U:ASLNNews ReleaseASLAN Pharmaceuticals Completes Enrolment in Second Cohort and Opens New Sites in US and Australia in ASLAN004 Atopic Dermatitis Study
2020-09-10 03:08U:ASLNNews ReleaseASLAN Pharmaceuticals to Present at H.C. Wainwright 22nd Annual Global Investment Conference
2020-08-24 03:28U:ASLNNews ReleaseASLAN Pharmaceuticals Resumes Recruitment of New Patients Into ASLAN004 Study
2020-08-07 03:00U:ASLNNews ReleaseASLAN Pharmaceuticals to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference 2020
2020-08-03 03:18U:ASLNNews ReleaseASLAN Pharmaceuticals Appoints Kenneth Kobayashi, MD, as Chief Medical Officer
2020-07-17 06:09U:ASLNNews ReleaseASLAN Pharmaceuticals Announces the Move of its Primary Listing to Nasdaq and Delisting From Taipei Exchange
2020-07-13 08:06U:ASLNNews ReleaseASLAN Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-05-11 05:35U:ASLNNews ReleaseASLAN Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update